Cargando…
Identification and validation of the model consisting of DDX49, EGFR, and T‐stage as a possible risk factor for lymph node metastasis in patients with lung cancer
INTRODUCTION: The lymph node metastasis stage of lung cancer is an important decisive factor in the need for postoperative adjuvant treatment and the difference between stage IIIa and stage IIIB that is the necessary information to distinguish whether surgery can be performed or not. The specificity...
Autores principales: | Zhang, Zhimin, Lian, Xiaojuan, Yue, Hongxu, Xiang, Debing, Niu, Zhongxi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234778/ https://www.ncbi.nlm.nih.gov/pubmed/37096455 http://dx.doi.org/10.1111/1759-7714.14892 |
Ejemplares similares
-
DDX49 is a novel biomarker and therapeutic target for lung cancer metastases
por: Lian, Xiaojuan, et al.
Publicado: (2019) -
BDH1 promotes lung cancer cell proliferation and metastases by PARP1‐mediated autophagy
por: Zhang, Zhimin, et al.
Publicado: (2023) -
Overexpression of DDX49 in prostate cancer is associated with poor prognosis
por: Tao, Junyue, et al.
Publicado: (2023) -
Lymph Node Ratio for Postoperative Staging of Laryngeal Squamous Cell Carcinoma with Lymph Node Metastasis
por: Wang, Yu-Long, et al.
Publicado: (2014) -
Blind spot in lung cancer lymph node metastasis: Cross‐lobe peripheral lymph node metastasis in early stage patients
por: Li, Ning, et al.
Publicado: (2018)